30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Extensive changes in resting-state oscillatory brain activity have recently been demonstrated using magnetoencephalography (MEG) in moderately advanced, non-demented Parkinson's disease patients relative to age-matched controls. 5 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with controls, the patients as a group showed the expected memory and metabolic profiles of impairment. 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Age-associated memory impairment (AAMI) is a common but disputed entity. 1 key finding →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is characterized by the degeneration and loss of cholinergic neurones in the nucleus basalis Meynert, located within the substantia innominata at the ventral surface of the basal forebrain. 3 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Noninvasive MRI biomarkers for Alzheimer's disease (AD) may enable earlier clinical diagnosis and the monitoring of therapeutic effectiveness. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Decrease of beta band synchronization occurs in mild AD, both in a resting condition and during a working memory task. 4 key findings →
Participants: 14 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Elevated tHcy levels are associated with decreased cognitive performance in nondemented elderly people, and the relation was most marked for psychomotor speed. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Ischemic leukoaraiosis is a consistent concomitant of vascular dementia. 1 key finding →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Frontotemporal lobar degeneration (FTLD) often overlaps clinically with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both of which have prominent eye movement abnormalities. 3 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
With the prospect of disease-modifying drugs that will target the physiopathological process of Alzheimer's disease, it is now crucial to increase the understanding of the atypical focal presentations of Alzheimer's disease, such as posterior cortical atrophy. 2 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Although a large variety of pharmaceutical therapies for treating disease have been developed in recent years, there has been little progress in disease prevention. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Pick-type histology was seen in 14 cases (21%) and tau histological changes associated with frontotemporal dementia (FTD) linked to chromosome 17 (FTDP-17) were present in 11 cases (16%). 5 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source
Saccades were measured by magnetic search coil technique in 13 patients with Alzheimer's disease and compared with those of 11 age-matched control subjects. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
When corrected for multiple comparisons, patients with visual hallucinations had significantly greater disease duration, treatment duration, motor severity and complications, sleep disturbances, in particular excessive daytime somnolence and rapid eye movement sleep behavioural disorder, disorders of mood, autonomic dysfunction and global, frontal and visuoperceptive cognitive dysfunction. 3 key findings →
Participants: 94 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with senile dementia of the Alzheimer type frequently have difficulty performing visual tasks. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
The results indicate a pathophysiologic association between nigrostriatal dysfunction and occipital glucose metabolic reduction in PD. 3 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
In this older population, cognitive impairment may share common age-related pathogenesis and risk factors with early AMD. 1 key finding →
Participants: 2,088 Evidence: low
Full summary, score breakdown and related studies → Original source
Most fd-OCT peripapillary RNFL and macular full-thickness and segmented inner retinal layers parameters were reduced in AD eyes compared to controls. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is the most prevalent cause of abnormal cognitive decline in older adults and commonly affects visual function. 5 key findings →
Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source
We reviewed the polysomnograms (PSGs) of 292 consecutive patients with sleep disorders (Parkinson's disease (PD), n=19, other sleep disorders, n=273) to investigate the sensitivity and specificity of the clinical diagnosis of rapid eye movement behavior disorder (RBD) compared with polysomnographic diagnosis. 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Clinical accounts of Alzheimer's disease (AD) suggest that some patients exhibit markedly diminished curiosity and initiative early in the course of their illness. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
The extent of amyloid deposition within the cerebellum and the cerebral cortex was assessed and compared, using anti-amyloid protein (A4) immunostaining and a novel methenamine silver method, in 20 patients aged between 60 and 77 years with Alzheimer's disease (AD), 29 patients aged between 13 and 71 years with Down's syndrome (DS), 26 demented patients with disorders other than AD and DS and in 20 non-demented elderly individuals of age range 60-102 years. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
One of the central aims in Alzheimer's disease (AD) research is the identification of clinically relevant drug targets. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Inflation Reduction Act Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden but also for higher-income beneficiaries. 1 key finding →
Design: modelling Participants: 1,677 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The differential diagnosis of Parkinson's diseases (PD) is challenging, especially in the early stages of the disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events